Advancing
a New Front
in the War against Cancer

Provectus Biopharmaceuticals is
developing advanced therapies designed
to target and destroy the deadliest cancers
- melanoma, liver and breast - while
minimizing side effects


PV-10

An Investigational Drug for Cancer

PH-10

An Investigational Drug for Psoriasis and Atopic Dermatitis

IN THE MEDIA

October 30, 2014

A New Cancer Drug Worked In Over 50% Of Patients In A Phase II Trial

In an article appearing on Forbes, Jon Fortenbury discusses the PV-10 phase 2 study results recently published in the journal Annals of Surgical Oncology showing that 51% of patients had an objective response with 26% having a complete reponse, and that for the 28 patients who had all of their disease treated, 50% ended the 16-week treatment period with no sign of disease.

October 22, 2014

Provectus Lists Partnering Opportunities for PV-10 and PH-10

P&T TV has posted two videos from coverage of the American Society of Clinical Oncology (ASCO) 2014 annual meeting. In these videos, titled "Intralesional Therapies Gain Recognition for Melanoma Treatment" and ""Very Impressive Data" for Rose Bengal 10% in Intralesional Melanoma", Dr. Merrick Ross, chief of the melanoma section in the Department of Surgical Oncology at MD Anderson Cancer Center in Houston, discusses the promising role of intralesional therapies for melanoma and the "very impressive data" from the phase 2 trial of PV-10.

October 21, 2014

"Very Impressive Data" for Rose Bengal 10% in Intralesional Melanoma

P&T TV has posted two videos from coverage of the American Society of Clinical Oncology (ASCO) 2014 annual meeting. In these videos, titled "Intralesional Therapies Gain Recognition for Melanoma Treatment" and ""Very Impressive Data" for Rose Bengal 10% in Intralesional Melanoma", Dr. Merrick Ross, chief of the melanoma section in the Department of Surgical Oncology at MD Anderson Cancer Center in Houston, discusses the promising role of intralesional therapies for melanoma and the "very impressive data" from the phase 2 trial of PV-10.

October 20, 2014

Current Perspectives on Intralesional Therapies

Dr. Sanjiv Agarwala of St. Luke's Cancer Center presented data on investigational new drug PV-10 for the treatment of melanoma on Saturday October 18 at the 2014 Beijing International Melanoma Congress. The presentation titled "Current Perspectives on Intralesional Therapies" was an abbreviated version of the presentation that Dr. Agarwala gave at the III Eurasian Melanoma and Skin Cancers Forum, in Suzdal, Russia.

October 19, 2014

Pink is the Color for Breast Cancer Cure

In a radio interview airing on eHealth Radio, Peter Culpepper, COO and CFO of Provectus Biopharmaceuticals discusses the progress of Provectus' investigational drug PV-10 in clinical trials for breast and skin cancers and how patients can find more information about clinical trials.

October 17, 2014

Q&A with Provectus Biopharmaceutical's COO/CFO, Peter Culpepper

In an article appearing on BioMedReports, Peter Culpepper, CFO, COO answers questions regarding the Memorandum of Understanding (MOU) with Sinopharm-China State Institute of Pharmaceutical Industry that Provectus entered into in August.

October 15, 2014

PV-10 delivers greatest effects when all lesions are injected

An article appearing on PharmiWeb.com reports on the latest data from the phase 2 trial of PV-10 for melanoma that were recently presented at the 2014 European Society for Medical Oncology (ESMO) Congress.

October 14, 2014

Overview of Intralesional Therapy for Melanoma: Focus on PV-10

Dr. Sanjiv Agarwala of St. Luke's Cancer Center recently presented data on investigational new drug PV-10 for the treatment of melanoma at the III Eurasian Melanoma and Skin Cancers Forum, in Suzdal, Russia. Slides from Dr. Agarwala's presentation are now available on the Provectus website.

October 14, 2014

PV-10 well-tolerated in treatment of refractory cutaneous melanoma

An article appearing in the Dermatology News section of Healio reports on the poster presented at the European Society of Medical Oncology Annual Congress (ESMO), showing that intralesional injection of PV-10 was well-tolerated in patients with refractory cutaneous melanoma, with just over half of patients meeting the primary study endpoint.

October 9, 2014

ERT's Scientific and Regulatory Consultants Support Phase III Oncology Trial

eResearch Technology (ERT) today announced that Provectus is collaborating with ERT's Clinical Outcome Assessment (COA) consultants on the upcoming Phase III trial of PV-10 for intralesional (IL) treatment of locally advanced cutaneous melanoma.

October 7, 2014

Melanoma treatment PV-10 shows promise in phase 2 trial

An article appearing on Dermatology Times reports on PV-10 study data recently presented at ESMO 2014 demonstrating effectiveness in the treatment of locally advanced cutaneous melanoma.

October 7, 2014

Intralesional injections show promise for cutaneous melanoma

An article appearing on eCancer News reports that the ESMO 2014 poster session ‘Melanoma and other skin tumours’, including a poster presentation on PV-10 efficacy, highlighted the emerging field of intralesional injections for cutaneous melanoma leading to tumour regression not only in the injected lesions, but also in 'bystander' lesions suggesting that the strategy is augmenting immune response.

October 7, 2014

Melanoma studies dominate ESMO

An article appearing on Melanoma News Today notes that melanoma studies dominated both the Presidential Symposium and poster sessions at the European Society for Medical Oncology (ESMO) 2014 meeting.

October 3, 2014

Cutaneous, Locoregional Melanomas Show High, Rapid Responses to Injection With Rose-Bengal Solution

An article appearing on FirstWord Pharma reports on data presented at the 2014 European Society for Medical Oncology (ESMO) Congress showing that patients who have all of their cutaneous and subcutaneous melanoma lesions injected with PV-10, experience high, complete treatment responses after only 1 or 2 injections.

October 1, 2014

Novel Rose Bengal Formulation Obliterates Lesions in Patients with Deadliest of Melanomas

An article appearing on Newswise reports on data presented at the European Society for Medical Oncology Congress in Spain showing that patients who received PV-10 into all existing melanoma lesions had an overall response rate of 71%.

August 28, 2014

Sinopharm Starts Talks With Provectus Over Anticancer

An article appearing in PharmAsia News reports that Sinopharm A-Think and Sinopharm-China State Institute of Pharmaceutical Industry, as part of Sinopharm's planned expansion in the China oncology sector, has signed a memorandum of Understanding (MoU) with Provectus to begin talks on PV-10 licensing.

August 7, 2014

Webcast: Conference Call August 7, 2014 4:00 PM EDT

Provectus management will host a conference call Thursday August 7, 2014 at 4:00 PM EDT.

August 4, 2014

Intralesional PV-10

Dr. Sanjiv Agarwala, Professor of Medicine, St. Luke's Cancer Center and Temple University, gave a presentation entitled "Intralesional PV-10" at the 10th European Association of Dermato Oncology (EADO) Congress in Vilnius, Lithuania.

July 29, 2014

Topical and intralesional immunotherapy for melanoma metastases

A DermNet New Zealand Trust article discusses investigational melanoma drugs, including PV-10, that are being used to deliver therapy directly into a local recurrence or metastasis with the goal of destroying the target lesion and stimulating regression of other, untreated lesions by inducing an immune response to the melanoma.

July 29, 2014

Intralesional Injections Trigger Immune Responses in Melanoma

An article published in Volume 5, Issue 12 of The ASCO Post discusses the emerging approach to treating metastatic melanoma by stimulating an immune response using intralesional injections of investigational melanoma drugs, including PV-10.

more...

PRESS RELEASES

October 31, 2014

Provectus Biopharmaceuticals, Inc. to Hold Quarterly Conference Call on Thursday, November 6, 2014

Provectus will host a quarterly conference call to update the market in general and shareholders in particular about developments at the Company. The call is scheduled for Thursday, November 6, 2014 at 4:00 PM EST.

October 28, 2014

Provectus' Intralesional PV-10 Clinical Data Published in the Annals of Surgical Oncology

Provectus announced today that data on its investigational new drug PV-10, obtained in clinical trial PV-10-MM-02 ( ClinicalTrials.gov Identifier NCT00521053), has been published by the Annals of Surgical Oncology (ASO).

October 16, 2014

Provectus' Intralesional PV-10 Clinical Data to Be Presented to the 2014 International Congress of the Society for Melanoma Research

Provectus announced today that Sanjiv S. Agarwala, MD, of St. Luke's University Hospital and Professor of Medicine at Temple University will present data on its investigational new drug PV-10 for the treatment of melanoma at the 11th International Congress of the Society for Melanoma Research in Zurich, Switzerland.

October 15, 2014

Provectus' Intralesional PV-10 and Co-Inhibitory Blockade Data to Be Presented at SITC 29th Annual Meeting

Provectus announced today that Shari Pilon-Thomas, Ph.D. from the Moffitt Cancer Center will present the abstract titled "Efficacy of Intralesional Injection with PV-10 in Combination with Co-Inhibitory Blockade in a Murine Model of Melanoma," at the Society for Immunotherapy of Cancer [SITC] 29th Annual Meeting in two time slots on Saturday, November 8: 12:30 pm - 2:00 pm and 6:00 pm - 7:30 pm.

October 14, 2014

INC Research Signs Agreement to Perform FDA Due Diligence Audit of Regulatory Documents for Provectus Biopharmaceuticals

Provectus announced today that it has retained INC Research, a leading, global Phase I to IV contract research organization, to conduct an FDA due diligence audit of its regulatory documents for PH-10 and PV-10.

October 8, 2014

Provectus' Intralesional PV-10 Clinical Data to Be Presented to the Eurasian Federation of Oncology

Provectus announced today that Dr. Sanjiv Agarwala of St. Luke's Cancer Center will present data on its investigational new drug PV-10 for the treatment of melanoma at the III Eurasian Melanoma and Skin Cancers Forum, in Suzdal, Russia.

October 7, 2014

Provectus' Intralesional PV-10 to Be Presented at the 2014 Beijing International Melanoma Congress

Provectus announced today that clinical data on its investigative new drug PV-10 for the treatment of melanoma will be presented at the 2014 Beijing International Melanoma Congress. The presentation by Dr. Sanjiv Agarwala of the St. Luke's Cancer Center is titled "Current Perspectives on Intralesional Therapies." It is scheduled for 5:30 pm local time, on Saturday, October 18, 2014.

September 29, 2014

Provectus Biopharmaceuticals Data Presented At ESMO 2014 Congress Show Ablative, Bystander Effects Of PV-10

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (www.pvct.com), announced today that data on its investigational agent PV-10 for intralesional (IL) treatment of locally advanced cutaneous melanoma was featured in a poster presentation on Sunday, September 28, 2014 during the European Society For Medical Oncology 2014 Congress in Madrid, Spain. The presentation showed that PV-10 elicits a high rate of response in injected tumors through its ablative effect, and additionally, that the durability of response as well as the bystander response in uninjected tumors implicate an additional immunologic mechanism secondary to ablation.

September 24, 2014

Provectus Biopharmaceuticals' PV-10 Clinical Data on Melanoma Now Available for European Society for Medical Oncology 2014 Congress

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (www.pvct.com), announced today that the abstract entitled, "Subgroup efficacy in patients receiving intralesional rose bengal to all existing melanoma in phase II study PV-10-MM-02," to be presented at the European Society for Medical Oncology 2014 Congress, is now available at
https://www.webges.com/cslide/library/esmo/browse/search/8ct#9faD03sJ.

September 23, 2014

Provectus' Intralesional PV-10 and Co-Inhibitory Blockade Data to Be Presented at SITC 29th Annual Meeting

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (www.pvct.com), announced today that a team of researchers led by Shari Pilon-Thomas, PhD from the Moffitt Cancer Center will present data at the Society for Immunotherapy of Cancer [SITC] 29th Annual Meeting with an abstract titled "Efficacy of Intralesional Injection with PV-10 in Combination with Co-Inhibitory Blockade in a Murine Model of Melanoma."

September 22, 2014

Provectus Biopharmaceuticals Appoints Christopher Kaplan to Its Strategic Advisory Board

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (www.pvct.com), announced today that it has appointed Christopher Kaplan to its Strategic Advisory Board effective immediately.

August 18, 2014

Provectus Signs Memorandum of Understanding with Sinopharm-China State Institute of Pharmaceutical Industry, and Sinopharm A-THINK Pharmaceutical Co., Ltd.

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (www.pvct.com), announced today that it entered into a Memorandum of Understanding ("MOU") with Sinopharm-China State Institute of Pharmaceutical Industry ("Sinopharm-CSIPI"), the leader among all pharmaceutical research institutes in China, and Sinopharm A-THINK Pharmaceutical Co., Ltd. ("Sinopharm A-THINK"), the only injectable anti-tumor drug research and development, manufacture and distribution integrated platform within Sinopharm Group.

August 6, 2014

Provectus Biopharmaceuticals Inc. to Commence Series of Quarterly Conference Calls on Thursday, August 7, 2014

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (www.pvct.com), will begin a series of regular quarterly conference calls to update the market in general and shareholders in particular about developments at the Company. In the future, these calls will coincide with the filing of the Company's 10-Q and 10-K filings with the Securities and Exchange Commission as appropriate.

July 23, 2014

Provectus Biopharmaceuticals' PV-10 Clinical Data on the Treatment of Melanoma to Be Presented at European Society for Medical Oncology 2014 Congress

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (www.pvct.com), will have clinical data on PV-10 presented at the European Society for Medical Oncology's 2014 Congress in Madrid, Spain.

July 8, 2014

Provectus Updates Shareholders in Its Annual CEO Letter

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (www.pvct.com), provides shareholders with an update on its corporate accomplishments, clinical progress and business development efforts during 2013, and shares as well as insights on upcoming plans and milestones for 2014.

June 19, 2014

Provectus Biopharmaceuticals, Inc. to Hold Conference Call Today to Detail Outline of Phase 3 Clinical Trial of PV-10 in Melanoma Treatment

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (www.pvct.com), wishes to remind interested parties that it will hold a conference call today, Thursday, June 19, 2014 at 4:00 p.m. EDT.

June 12, 2014

Provectus Biopharmaceuticals to Discuss Outline of Phase 3 Clinical Trial Of PV-10 To Treat Melanoma on Conference Call

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (www.pvct.com), announced today that it will hold a conference call on Thursday, June 19, 2014, at 4 pm Eastern Daylight Time.

June 3, 2014

PV-10 Data Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting Defines Path Forward for Provectus Biopharmaceuticals, Inc.

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (www.pvct.com), announced today that data on its investigational agent PV-10 for intralesional (IL) treatment of solid tumors were featured in two presentations in the Poster Highlights Session, Melanoma/Skin Cancers, on June 2, 2014 during the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL.

May 27, 2014

Provectus Biopharmaceuticals Inc. to Hold Conference Call Tuesday, June 3, 2014

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (www.pvct.com), announced today that it will hold a conference call on Tuesday, June 3, 2014 at 8:30 a.m. EDT.

May 23, 2014

Provectus Biopharmaceuticals Inc. Reaffirms Its Commitment to Bringing PV-10 to Market Notwithstanding FDA Decision on Breakthrough Therapy Designation

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, has received notification from the United States Food and Drug Administration that the data upon which the Company based its request for designation of PV-10 as a Breakthrough Therapy for the treatment of patients with locally advanced cutaneous melanoma was insufficient to demonstrate substantial improvement over existing therapies. As a result, the FDA has declined to designate PV-10 as a Breakthrough Therapy at this time. Further data may cause the Agency to revisit this decision at a later date. PV-10 is the Company's novel investigational drug for solid tumors.

more...